NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
NCT ID: NCT00206180
Last Updated: 2009-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
120 participants
INTERVENTIONAL
2004-06-30
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
NCT00206024
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
NCT00242736
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
NCT00317044
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
NCT00641602
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
NCT00295685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
esomeprazole magnesium (oral medication)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have moderate to severe erosive esophagitis
Exclusion Criteria
* Severe heart, lung, liver or kidney disease
* Esophagitis not related to acid reflux
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nexium Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Alabaster, Alabama, United States
Research Site
Anaheim, California, United States
Research Site
Dinuba, California, United States
Research Site
Fresno, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Research Site
Bridgeport, Connecticut, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
New Port Richey, Florida, United States
Research Site
Zephyrhills, Florida, United States
Research Site
Decatur, Georgia, United States
Research Site
Rome, Georgia, United States
Research Site
Savannah, Georgia, United States
Research Site
Oakbrook Terrace, Illinois, United States
Research Site
Urbana, Illinois, United States
Research Site
Louisville, Kentucky, United States
Research Site
Covington, Louisiana, United States
Research Site
Baltimore, Maryland, United States
Research Site
Chevy Chase, Maryland, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Troy, Michigan, United States
Research Site
Egg Harbor, New Jersey, United States
Research Site
Passaic, New Jersey, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Jacksonville, North Carolina, United States
Research Site
Duncansville, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
North Providence, Rhode Island, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Ogden, Utah, United States
Research Site
Bellevue, Washington, United States
Research Site
Spokane, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007 Mar 1;25(5):617-28. doi: 10.1111/j.1365-2036.2006.03235.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9612L00062
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.